Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?

Aliment Pharmacol Ther. 2018 Jan;47(1):146-147. doi: 10.1111/apt.14321.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biological Products
  • Crohn Disease*
  • Digestive System Surgical Procedures
  • Humans
  • Infliximab
  • Tumor Necrosis Factor-alpha*

Substances

  • Biological Products
  • Tumor Necrosis Factor-alpha
  • Infliximab